<DOC>
	<DOCNO>NCT00047216</DOCNO>
	<brief_summary>RATIONALE : Tipifarnib may stop growth tumor cell block enzymes necessary tumor cell growth . PURPOSE : Phase II trial study effectiveness tipifarnib treat patient recurrent bladder cancer .</brief_summary>
	<brief_title>Tipifarnib Treating Patients With Recurrent Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine 1-year recurrence-free survival rate patient stage 0 I recurrent transitional cell carcinoma bladder treat tipifarnib . OUTLINE : This multicenter study . Patients receive oral tipifarnib twice daily day 1-21 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 37 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma ( TCC ) bladder without associate carcinoma situ Stage 0 I ( Ta T1 ) Grade 1 , 2 , 3 TCC Cystoscopically histologically confirm recurrent disease least 1 course standard firstline intravesical therapy ( e.g. , BCG mitomycin ) within past 12 month Complete transurethral resection bladder tumor perform within past 4 week Rendered clinically cystoscopically tumor free Negative cytology No upper tract TCC intravenous pyelogram , retrograde pyelogram , CT scan kidney ( contrast ) PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 1 year Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin normal AST/ALT great 2.5 time upper limit normal ( ULN ) Renal Creatinine great 1.25 time ULN OR Creatinine clearance least 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No uncontrolled hypertension Other Able swallow retain oral medication Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction compound similar chemical biological composition study drug ( e.g. , imidazole ketoconazole imidazolebased antifungal agent , losartan , metronidazole , cimetidine ) No prior concurrent malignancy within past 5 year except nonmelanomatous skin cancer No uncontrolled concurrent illness would preclude study participation No ongoing active infection No active peptic ulcer disease No psychiatric illness social situation would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No prior systemic chemotherapy bladder cancer Endocrine therapy Not specify Radiotherapy No prior radiotherapy bladder cancer Surgery See Disease Characteristics Other No singledose posttransurethral resection ( TUR ) adjuvant intravesical therapy ( TUR perform immediately precede study entry ) At least 4 week since prior investigational agent No concurrent commercial investigational agent therapy malignancy No concurrent therapy bladder cancer No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>